-
Ahn SH, Park YK, Park ES, Kim JH, Kim DH, Lim KH, Jang MS, Choe WH, Ko SY, Sung IK, Kwon SY, Kim KH, 2014: The impact of the hepatitis B virus polymerase rtA181T mutation on replication and drug resistance is potentially affected by overlapping changes in surface gene[J]. J Virol, 88, 6805-6818. doi: 10.1128/JVI.00635-14
-
Cao L, Wu C, Shi H, Gong Z, Zhang E, Wang H, Zhao K, Liu S, Li S, Gao X, Wang Y, Pei R, Lu M, Chen X, 2014: Coexistence of hepatitis B virus quasispecies enhances viral replication and the ability to induce host antibody and cellular immune responses[J]. J Virol, 88, 8656-8666. doi: 10.1128/JVI.01123-14
-
Colledge D, Soppe S, Yuen L, Selleck L, Walsh R, Locarnini S, Warner N, 2017: Stop codons in the hepatitis B surface proteins are enriched during antiviral therapy and are associated with host cell apoptosis[J]. Virology, 501, 70-78. doi: 10.1016/j.virol.2016.11.007
-
Lai MW, Yeh CT, 2008: The oncogenic potential of hepatitis B virus rtA181T/surface truncation mutant[J]. Antivir Ther, 13, 875-879.
-
Lai MW, Huang SF, Hsu CW, Chang MH, Liaw YF, Yeh CT, 2009: Identification of nonsense mutations in hepatitis B virus S gene in patients with hepatocellular carcinoma developed after lamivudine therapy[J]. Antivir Ther, 14, 249-261.
-
Lambert C, Doring T, Prange R, 2007: Hepatitis B virus maturation is sensitive to functional inhibition of ESCRT-Ⅲ, Vps4, and gamma 2-adaptin[J]. J Virol, 81, 9050-9060. doi: 10.1128/JVI.00479-07
-
Lee SA, Kim K, Kim H, Kim BJ, 2012: Nucleotide change of codon 182 in the surface gene of hepatitis B virus genotype C leading to truncated surface protein is associated with progression of liver diseases[J]. J Hepatol, 56, 63-69. doi: 10.1016/j.jhep.2011.06.028
-
Li S, Zhao K, Liu S, Wu C, Yao Y, Cao L, Hu X, Zhou Y, Wang Y, Pei R, Lu M, Chen X, 2015: HBsAg sT123 N mutation induces stronger antibody responses to HBsAg and HBcAg and accelerates in vivo HBsAg clearance[J]. Virus Res, 210, 119-125. doi: 10.1016/j.virusres.2015.08.004
-
Liu Y, Wang C, Zhong Y, Li X, Dai J, Ren X, Xu Z, Li L, Yao Z, Ji D, Wang L, Zhang L, Wong VW, Zoulim F, Xu D, 2011: Genotypic resistance profile of hepatitis B virus (HBV) in a large cohort of nucleos(t)ide analogue-experienced Chinese patients with chronic HBV infection[J]. J Viral Hepat, 18, e29-e39. doi: 10.1111/j.1365-2893.2010.01360.x
-
Liu Y, Xu Z, Wang Y, Li X, Liu L, Chen L, Xin S, Xu D, 2014: rtM204Q may serve as a novel lamivudine-resistance-associated mutation of hepatitis B virus[J]. PLoS ONE, 9, e89015-. doi: 10.1371/journal.pone.0089015
-
Lok AS, McMahon BJ, Brown RS Jr, Wong JB, Ahmed AT, Farah W, Almasri J, Alahdab F, Benkhadra K, Mouchli MA, Singh S, Mohamed EA, Abu Dabrh AM, Prokop LJ, Wang Z, Murad MH, Mohammed K, 2016: Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis[J]. Hepatology, 63, 284-306. doi: 10.1002/hep.28280
-
Meng Z, Xu Y, Wu J, Tian Y, Kemper T, Bleekmann B, Roggendorf M, Yang D, Lu M, 2008: Inhibition of hepatitis B virus gene expression and replication by endoribonuclease-prepared siRNA[J]. J Virol Methods, 150, 27-33. doi: 10.1016/j.jviromet.2008.02.008
-
Patient R, Hourioux C, Sizaret PY, Trassard S, Sureau C, Roingeard P, 2007: Hepatitis B virus subviral envelope particle morphogenesis and intracellular trafficking[J]. J Virol, 81, 3842-3851. doi: 10.1128/JVI.02741-06
-
Patient R, Hourioux C, Roingeard P, 2009: Morphogenesis of hepatitis B virus and its subviral envelope particles[J]. Cell Microbiol, 11, 1561-1570. doi: 10.1111/cmi.2009.11.issue-11
-
Pollicino T, Cacciola I, Saffioti F, Raimondo G, 2014: Hepatitis B virus PreS/S gene variants: pathobiology and clinical implications[J]. J Hepatol, 61, 408-417. doi: 10.1016/j.jhep.2014.04.041
-
Qin B, Budeus B, Cao L, Wu C, Wang Y, Zhang X, Rayner S, Hoffmann D, Lu M, Chen X, 2013: The amino acid substitutions rtP177G and rtF249A in the reverse transcriptase domain of hepatitis B virus polymerase reduce the susceptibility to tenofovir[J]. Antiviral Res, 97, 93-100. doi: 10.1016/j.antiviral.2012.12.007
-
Warner N, Locarnini S, 2008: The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound[J]. Hepatology, 48, 88-98. doi: 10.1002/hep.v48:1
-
Wu C, Zhang X, Tian Y, Song J, Yang D, Roggendorf M, Lu M, Chen X, 2010: Biological significance of amino acid substitutions in hepatitis B surface antigen (HBsAg) for glycosylation, secretion, antigenicity and immunogenicity of HBsAg and hepatitis B virus replication[J]. J Gen Virol, 91, 483-492. doi: 10.1099/vir.0.012740-0
-
Wu C, Deng W, Deng L, Cao L, Qin B, Li S, Wang Y, Pei R, Yang D, Lu M, Chen X, 2012: Amino acid substitutions at positions 122 and 145 of hepatitis B virus surface antigen (HBsAg) determine the antigenicity and immunogenicity of HBsAg and influence in vivo HBsAg clearance[J]. J Virol, 86, 4658-4669. doi: 10.1128/JVI.06353-11
-
Xu S, Pei R, Guo M, Han Q, Lai J, Wang Y, Wu C, Zhou Y, Lu M, Chen X, 2012: Cytosolic phospholipase A2 gamma is involved in hepatitis C virus replication and assembly[J]. J Virol, 86, 13025-13037. doi: 10.1128/JVI.01785-12
-
Yao Y, Yang B, Cao H, Zhao K, Yuan Y, Chen Y, Zhang Z, Wang Y, Pei R, Chen J, Hu X, Zhou Y, Lu M, Wu C, Chen X, 2018: RBM24 stabilizes hepatitis B virus pregenomic RNA but inhibits core protein translation by targeting the terminal redundancy sequence[J]. Emerg Microbes Infect, 7, 86-.
-
Yeh CT, 2010: Development of HBV S gene mutants in chronic hepatitis B patients receiving nucleotide/nucleoside analogue therapy[J]. Antivir Ther, 15, 471-475. doi: 10.3851/IMP1552
-
Yeh CT, Chen T, Hsu CW, Chen YC, Lai MW, Liang KH, Chen TC, 2011: Emergence of the rtA181T/sW172* mutant increased the risk of hepatoma occurrence in patients with lamivudine-resistant chronic hepatitis B[J]. BMC Cancer, 11, 398-. doi: 10.1186/1471-2407-11-398
-
Zhang X, Zhang E, Ma Z, Pei R, Jiang M, Schlaak JF, Roggendorf M, Lu M, 2011: Modulation of hepatitis B virus replication and hepatocyte differentiation by MicroRNA-1[J]. Hepatology, 53, 1476-1485. doi: 10.1002/hep.24195
-
Zhao K, Wu C, Yao Y, Cao L, Zhang Z, Yuan Y, Wang Y, Pei R, Chen J, Hu X, Zhou Y, Lu M, Chen X, 2017: Ceruloplasmin inhibits the production of extracellular hepatitis B virions by targeting its middle surface protein[J]. J Gen Virol, 98, 1410-1421. doi: 10.1099/jgv.0.000794
-
Zhao L, Li X, Cheng Y, Chen R, Shao J, Zhou Y, Li Q, Liao H, Zhao Y, Liu L, Su H, Liu Y, Liu Y, Xu D, 2018: Hepatitis B virus rtA181T/sW172non-stop mutation may increase resistance fold to adefovir- and entecavir-resistant mutants compared to rtA181T/sW172* mutation[J]. Antiviral Res, 154, 26-34. doi: 10.1016/j.antiviral.2018.04.003
-
Zoulim F, Locarnini S, 2009: Hepatitis B virus resistance to nucleos(t)ide analogues[J]. Gastroenterology, 137, e1591-e1592. doi: 10.1053/j.gastro.2009.08.063